300452.SHE Anhui Sunhere Pharmaceutical Excipients Co Ltd
- Market cap
- CNY 2.73B
- P/E
- 16.4x
- P/B
- 2.50x
- ROE
- 15.7%
- Dividend yield
- 2.61%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 300452.SHE undervalued?
Graham number300452.SHE trades 35.0% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Anhui Sunhere Pharmaceutical Excipients Co Ltd fundamental analysis
No fundamental analysis for Anhui Sunhere Pharmaceutical Excipients Co Ltd yet.
Anhui Sunhere Pharmaceutical Excipients Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Anhui Sunhere Pharmaceutical Excipients Co Ltd
Anhui Sunhere Pharmaceutical Excipients Co.,Ltd. engages in the research and development, production, and sale of new pharmaceutical excipients in China. The company provides fillers, adhesives, disintegrants, lubricants, coating materials and other commonly used oral solid preparations. It also offers microcrystalline cellulose, hydroxypropyl methylcellulose, low-substituted hydroxypropyl cellulose, sodium methyl starch, magnesium stearate, and film coating powder, as well …
Full company profileAnhui Sunhere Pharmaceutical Excipients Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Anhui Sunhere Pharmaceutical Excipients Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 286M | 339M | 429M | 464M | 531M | 617M | 705M | 839M | 883M | 943M | 1.02B |
| Gross Profit | 96.8M | 105M | 145M | 170M | 164M | 178M | 209M | 265M | 273M | 299M | 321M |
| Operating Income | 53.6M | 60.8M | 88.4M | 104M | 109M | 99.7M | 136M | 185M | 143M | 194M | 206M |
| EBITDA | 69.0M | 77.1M | 107M | 123M | 140M | 133M | 174M | 229M | 206M | 265M | 205M |
| Net Income | 48.8M | 50.3M | 70.1M | 84.4M | 93.9M | 89.3M | 131M | 162M | 119M | 177M | 167M |
| EPS | 0.21 | 0.21 | 0.30 | 0.36 | 0.41 | 0.38 | 0.56 | 0.67 | 0.51 | 0.75 | 0.71 |
| Balance Sheet | |||||||||||
| Total Assets | 513M | 666M | 710M | 810M | 901M | 963M | 1.18B | 1.54B | 1.56B | 1.71B | 1.81B |
| Total Liabilities | 110M | 166M | 152M | 214M | 246M | 257M | 392M | 607M | 584M | 639M | 679M |
| Shareholders' Equity | 403M | 441M | 493M | 526M | 585M | 640M | 723M | 866M | 905M | 1.01B | 1.06B |
| Cash & Short-term Investments | 117M | 128M | 87.5M | 184M | 300M | 329M | 365M | 686M | 708M | 299M | 203M |
| Total Debt | 36.8M | 64.2M | 54.2M | 11.1M | 40.0M | 31.0M | 39.8M | 298M | 305M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 55.3M | 63.5M | 74.8M | 79.5M | 85.6M | 104M | 133M | 143M | 118M | 192M | - |
| Capital Expenditure | 15.3M | 25.1M | 81.8M | 59.8M | 21.1M | 31.5M | 67.3M | 54.9M | 27.9M | 40.7M | 73.3M |
| Free Cash Flow | 40.1M | 38.4M | -7.05M | 19.6M | 64.5M | 72.3M | 65.5M | 77.4M | 90.4M | 151M | 115M |
| Ratios | |||||||||||
| ROE | 12.1% | 11.4% | 14.2% | 16.0% | 16.1% | 13.9% | 18.1% | 18.7% | 13.2% | 17.5% | 15.7% |
| ROA | 9.5% | 7.6% | 9.9% | 10.4% | 10.4% | 9.3% | 11.1% | 10.5% | 7.7% | 10.3% | 9.2% |
| Net Profit Margin | 17.0% | 14.8% | 16.4% | 18.2% | 17.7% | 14.5% | 18.6% | 19.2% | 13.5% | 18.7% | 16.3% |
| Debt to Equity | 0.09x | 0.15x | 0.11x | 0.02x | 0.07x | 0.05x | 0.06x | 0.34x | 0.34x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Anhui Sunhere Pharmaceutical Excipients Co Ltd dividends
- Dividend yield
- 2.61%
- Forward dividend
- 0.30 CNY
- Payout ratio
- 40.5%
- Ex-dividend date
- Jun 10, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 71.4M | 0.30 | 40.5% |
| 2024 | CNY 59.0M | 0.25 | 49.4% |
| 2023 | CNY 59.8M | 0.25 | 37.0% |
| 2022 | CNY 54.1M | 0.23 | 41.4% |
| 2021 | CNY 45.1M | 0.19 | 50.5% |
| 2020 | CNY 34.4M | 0.15 | 36.6% |
| 2019 | CNY 27.8M | 0.12 | 33.0% |
| 2018 | CNY 22.6M | 0.10 | 32.2% |
| 2017 | CNY 19.9M | 0.08 | 39.6% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.3:1 on May 26, 2022.
Who owns Anhui Sunhere Pharmaceutical Excipients Co Ltd
- Insiders 40.03%
- Institutions 1.24%
- Public & others 58.73%
- Shares outstanding 234M
- Free float 143M
Anhui Sunhere Pharmaceutical Excipients Co Ltd company profile
- Company name
- Anhui Sunhere Pharmaceutical Excipients Co Ltd
- Ticker
- 300452.SHE
- ISIN
- CNE100001ZH5
- Exchange
- Shenzhen Stock Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 1,130
- Fiscal year end
- December
- Address
- Huainan Economic and Technological Development Zone,, Huainan, China, 232007
- Phone
- 86 55 4279 6116
- Website
- shanhe01.com
About Anhui Sunhere Pharmaceutical Excipients Co Ltd
Anhui Sunhere Pharmaceutical Excipients Co.,Ltd. engages in the research and development, production, and sale of new pharmaceutical excipients in China. The company provides fillers, adhesives, disintegrants, lubricants, coating materials and other commonly used oral solid preparations. It also offers microcrystalline cellulose, hydroxypropyl methylcellulose, low-substituted hydroxypropyl cellulose, sodium methyl starch, magnesium stearate, and film coating powder, as well as food additive products; and starch, and yellow dextrin products. The company serve textile, papermaking, petroleum, chemical, pharmaceutical, building materials, food, health products, medical aesthetics, cosmetics, and new energy fields. It also exports its products. Anhui Sunhere Pharmaceutical Excipients Co.,Ltd. was founded in 2001 and is based in Huainan, China.
Anhui Sunhere Pharmaceutical Excipients Co Ltd management
5- Mr. Dao Cai SongGM & Non-Independent Director · born 1970
- Mr. Qi LiuHead of Finance & Secretary of the Board · born 1972
- Ms. Hanfang LeiDeputy GM & Director · born 1981
- Mr. Zihu LiuDeputy General Manager · born 1970
- Juan YeAccounting Supervisor